FDA Asks Novo Nordisk For More Information On Semaglutide Label Expansion Application

The FDA has issued a Refusal to File letter covering Novo Nordisk A/S' NVO label expansion application for once-weekly semaglutide 2.0 mg to treat type 2 diabetes, which was filed on 20 January.

  • The FDA has requested additional information in the letter, including data relating to a proposed new manufacturing site.
  • The company will resubmit the application to FDA during the second quarter of 2021.
  • Though there is a requirement for additional information for resubmission, Novo Nordisk believes the already completed trial program will be sufficient for approval of the label expansion application.
  • Price Action: NVO shares are trading 1.59% lower at $69.92 in premarket on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralType 2 Diabetes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!